Emergent BioSolutions Inc.
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 3 disclosed transactions, Emergent BioSolutions Inc. concentrates its licensing activity in InfectiousDisease, Oncology. Emergent BioSolutions Inc. pays a 0.70x discount to market median. Their most common deal structure is Acquisition, with an average disclosed value of $244M. Most recent activity: 2022.
Pipeline coverage & gaps
Emergent BioSolutions Inc. has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 2 | $232M | $356M |
| License | 1 | — | $19M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2022 | brincidofovir (TEMBEXA) | Chimerix, Inc. | smallpox | approved | $238M | $351M |
| 2022 | TEMBEXA | Chimerix | smallpox | approved | $225M | $362M |
| 2011 | Zanolimumab | Genmab A/S | cutaneous T-cell lymphoma, peripheral T-cell lymphoma | phase_3 | — | $19M |
How this is computed
For each Emergent BioSolutions Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.470, clamped to [0.7, 1.5].